Aurora Therapeutics

Based in Cambridge, US, Aurora Therapeutics specializes in personalized gene editing solutions targeting rare genetic diseases through advanced CRISPR technology, addressing significant medical needs. Aurora Therapeutics, founded in 2026, focuses on developing personalized gene editing therapies. The company has not undergone any notable pivots since its inception. It has established its headquarters in Cambridge, US.

Aurora was founded with the backing of a team of seasoned professionals in genetic research. In January 2026, the company raised USD 16. 00 mn in a Seed round led by Menlo Ventures, bringing the total amount raised to USD 16. 00 mn.

The firm has completed 1 deal to date. Aurora Therapeutics specializes in personalized gene editing solutions targeting rare genetic diseases. The company utilizes advanced CRISPR technology, enabling the rapid and precise customization of gene editing therapies for a multitude of genetic mutations that contribute to rare diseases. This innovative approach addresses a significant unmet medical need, as most existing therapies are incapable of targeting the vast array of rare mutations effectively.

Aurora's solutions aim to deliver tailored treatments directly to patients suffering from these conditions, thereby improving therapeutic outcomes. The company's offerings are designed for a broad client base, including healthcare providers, biotechnology firms, and research institutions primarily located in North America and Europe, where there is a high demand for effective treatments for rare genetic disorders. Aurora Therapeutics generates revenue through strategic partnerships and collaborations with healthcare organizations and research institutions engaged in genetic research and therapy development. The business model is focused on B2B transactions, where Aurora provides gene editing technologies and services to these entities.

Revenue streams may include licensing agreements for their proprietary gene editing platform, as well as fees for custom gene editing services tailored to specific client needs. These transactions are structured around project-based pricing or retainer agreements that outline the scope of services provided. While specific pricing plans or flagship products are not disclosed, the company's innovative platform positions it in the rapidly evolving field of personalized medicine, catering to the growing demand for effective treatments for rare genetic diseases. In January 2026, Aurora Therapeutics raised USD 16.

00 mn in Seed funding to enhance its capabilities in personalized gene editing therapies. The funding will assist in advancing CRISPR engineering, AI-driven editor design, and regulatory strategies to develop treatments for rare genetic mutations, with an initial focus on phenylketonuria (PKU). The company plans to expand its market presence into additional regions in North America and Europe by the end of 2026, aiming to address a broader audience needing tailored genetic therapies.